Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-19-142945
Filing Date
2019-05-09
Accepted
2019-05-09 16:02:15
Documents
53
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d739656d10q.htm 10-Q 385296
2 EX-31.1 d739656dex311.htm EX-31.1 10703
3 EX-31.2 d739656dex312.htm EX-31.2 10688
4 EX-32.1 d739656dex321.htm EX-32.1 5292
11 GRAPHIC g739656g55z44.jpg GRAPHIC 30102
  Complete submission text file 0001193125-19-142945.txt   4504910

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT meip-20190331.xml EX-101.INS 1264322
6 XBRL TAXONOMY EXTENSION SCHEMA meip-20190331.xsd EX-101.SCH 34209
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE meip-20190331_cal.xml EX-101.CAL 28270
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE meip-20190331_def.xml EX-101.DEF 230795
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE meip-20190331_lab.xml EX-101.LAB 297517
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE meip-20190331_pre.xml EX-101.PRE 259604
Mailing Address 3611 VALLEY CENTER DRIVE SUITE 500 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTER DRIVE SUITE 500 SAN DIEGO CA 92130 858-792-6300
MEI Pharma, Inc. (Filer) CIK: 0001262104 (see all company filings)

EIN.: 510407811 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-50484 | Film No.: 19810389
SIC: 2834 Pharmaceutical Preparations